Storage and handling
Other Information Store at 15° - 30°C (59° - 86°F).
Other Information Store at 15° - 30°C (59° - 86°F).
Uses Temporarily relieves:
Warnings
Do not exceed recommended dosage.
Ask a doctor before use if you have
Stop use and ask a doctor if
If pregnant or breast-feeding, ask a
health professional before use.
Keep out of the reach of children. In case of accidental overdose, get medical help or contact a Poison Control
Center right away.
Directions Take this medication with a full glass of water after each dose to help loosen mucus in the lungs
| Adults and children 12 years of age and over: | 2 teaspoonfuls (10mL) every 4 hours, not to exceed 12 teasoonfuls in 24 hours |
| Children 6 to under 12 years of age: | 1 teaspoonful (5 mL) every 4 hours, not to exceed 6 teaspoonfuls in 24 hours |
| *Children under 6 years of age: | Consult a doctor. |
* Giving a higher dose than recommended by a doctor could result in serious side effects.
Other Information
Store at 15° - 30°C (59° - 86°F).
Inactive Ingredients
Bitter Mask, Citric Acid, Cotton Candy Flavor, Glycerin, Propylene Glycol, Purified Water, Sodium Citrate, Sodium Saccharin, Sorbitol.
Questions? Comments?
To report a serious adverse event or obtain product
information, contact 1-866-959-4880
23359-040-16
Ninjacof-XG
Cotton Candy
Flavor
CENTURION
16 fl oz (473 mL)
Tamper evident by foil seal under cap. Do not use if foil
seal is broken or missing.
Dispense in a tight, light-resistant container as defined
in the USP/NF with a child-resistant closure.
Store at controlled room temperature,
15°-30°C (59°-86°F)
KEEP THIS AND ALL MEDICATIONS
OUT OF THE REACH OF CHILDREN.
Manufactured for:
Centurion Labs, LLC Birmingham, AL 35243

| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1114026 | codeine phosphate 8 MG / guaiFENesin 200 MG in 5 mL Oral Solution | PSN | 3 |
| 1595214 | Ninjacof-XG 8 MG / 200 MG in 5 mL Oral Solution | PSN | 3 |
| 1595214 | codeine phosphate 1.6 MG/ML / guaifenesin 40 MG/ML Oral Solution [Ninjacof XG] | SBD | 3 |
| 1114026 | codeine phosphate 1.6 MG/ML / guaifenesin 40 MG/ML Oral Solution | SCD | 3 |
| 1114026 | codeine phosphate 8 MG / guaifenesin 200 MG per 5 ML Oral Solution | SY | 3 |
| 1595214 | Ninjacof XG (codeine phosphate 8 MG / guaifenesin 200 MG) per 5 ML Oral Solution | SY | 3 |
| Class | Version | Type | Effective |
|---|---|---|---|
| CODEINE ANHYDROUS Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| GUAIFENESIN Pharmacologic Class Indexing | 1 | Indexing - Pharmacologic Class | 20211129 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 23359-040-16 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-3a45-f424-e053-dadaa90a57ce | Ninjacof-XG |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 23359-040-16 | Ninjacof-XG | 473 mL in 1 BOTTLE | LIQUID | 473 | 3 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 23359-040-16 | ML - Milliliter | 23359-040 | 4d230bab-c7dc-4959-bac4-f1b330db11c1 | 1 | 2014-12-01 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Codeine Phosphate | ACTIVE INGREDIENT | GSL05Y1MN6 | 3 | |
| Guaifenesin | ACTIVE INGREDIENT | 495W7451VQ | 3 | |
| Codeine Anhydrous | ACTIVE MOIETY | UX6OWY2V7J | 3 | |
| Guaifenesin | ACTIVE MOIETY | 495W7451VQ | 3 | |
| Citric Acid Monohydrate | INACTIVE INGREDIENT | 2968PHW8QP | 3 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 3 | |
| Propylene Glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 3 | |
| Saccharin Sodium | INACTIVE INGREDIENT | SB8ZUX40TY | 3 | |
| Sodium Citrate | INACTIVE INGREDIENT | 1Q73Q2JULR | 3 | |
| Sorbitol | INACTIVE INGREDIENT | 506T60A25R | 3 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 23359-040 | 23359-040-16 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Codeine Phosphate | GSL05Y1MN6 | ACTIB |
| Guaifenesin | 495W7451VQ | ACTIB |
| Citric Acid Monohydrate | 2968PHW8QP | IACT |
| Glycerin | PDC6A3C0OX | IACT |
| Propylene Glycol | 6DC9Q167V3 | IACT |
| Water | 059QF0KO0R | IACT |
| Sodium Citrate | 1Q73Q2JULR | IACT |
| Saccharin Sodium | SB8ZUX40TY | IACT |
| Sorbitol | 506T60A25R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sorbitol | SORBITOL | 506T60A25R | SYSTEM / TOPICAL | 6300 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY / NASAL | 9 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | EMULSION / TOPICAL | 0.11 %w/w | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, EXTENDED RELEASE / ORAL | 428 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / TOPICAL | 0.01 %w/v | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / ORAL | 446 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / RECTAL | 3315 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, COATED / ORAL | 12.96 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, FILM COATED / ORAL | 5 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | SUSPENSION / ORAL | 45000 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SWAB / TOPICAL | 0.05 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TROCHE / ORAL | 12 mg | ||
| Saccharin Sodium | SACCHARIN SODIUM | SB8ZUX40TY | GRANULE, FOR SOLUTION / ORAL | 5.5 mg/120ml | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / SUBLINGUAL | 36 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | GUM, CHEWING / BUCCAL | 5110 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / ORAL | 114 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | PASTE / DENTAL | 0.5 %w/w | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EXTENDED RELEASE / ORAL | 45 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SUSPENSION / ORAL | 840 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GRANULE, FOR SUSPENSION / ORAL | 113 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAVENOUS | 2068 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CONCENTRATE / ORAL | 5.3 mg/1ml | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET / SUBLINGUAL | 50.5 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| Saccharin Sodium | SACCHARIN SODIUM | SB8ZUX40TY | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / TOPICAL | 8 %w/w | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / ORAL | 2590 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INFILTRATION | 0.02 %w/v | ||
| Saccharin Sodium | SACCHARIN SODIUM | SB8ZUX40TY | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.05 %w/w | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DOUCHE / VAGINAL | 0.07 %w/w | ||
| Sorbitol | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / RECTAL | 1214 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SHAMPOO, SUSPENSION / TOPICAL | 0.25 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | SOLUTION / OPHTHALMIC | 6 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO / TOPICAL | 8 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRACARDIAC | 1.05 %w/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / OPHTHALMIC | 0.44 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| Saccharin Sodium | SACCHARIN SODIUM | SB8ZUX40TY | SOLUTION / DENTAL | 0.05 %w/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAOCULAR | 1 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / VAGINAL | 6.4 %w/w | ||
| Saccharin Sodium | SACCHARIN SODIUM | SB8ZUX40TY | CAPSULE / ORAL | 24 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 38 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 47ba8466-68bc-4b31-89c9-6340dff26e9a | 98f8bf79-825d-c04d-0edd-826d4752736d | 2014-11-20 | Warnings | 47ba8466-68bc-4b31-89c9-6340dff26e9a 98f8bf79-825d-c04d-0edd-826d4752736d |
Adverse event summaries are temporarily unavailable. Other product information remains available.